References
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults
hospitalized with severe COVID-19. N Engl J Med 2020; 382:1787-1799.
- RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted
to hospital with COVID-19 (RECOVERY): a randomised, controlled,
open-label, platform trial. Lancet 2020;396:1345-1352.
- The RECOVERY Collaborative Group. Effect of hydroxychloroquine in
hospitalized patients with COVID-19. N Engl J Med 2020;383:2030-2040
- Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with
hydroxychloroquine or azithromycin with in-hospital mortality in
patients with COVID-19 in New York state. JAMA 2020;323:2493-2502.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or
without azithromycin in mild-to-moderate COVID-19. N Engl J Med
2020;383:2041-2052.
- WHO Solidarity trial consortium. Repurposed antiviral drugs for
COVID-19 –interim WHO Solidarity trial results. N Engl J Med 2020
December 2. [Epub ahead of print]
- Beigel JH, Tomashek KM, Dodd LE. et al. Remdesivir for the treatment
of COVID-19—final report. N Engl J Med 2020; 383: 1813-1826.
- Cai Q, Yanga M, Liu D, et al. Experimental treatment with favipiravir
for COVID-19: An open-label control study. Engineering
2020;6:1192-1198.
- Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for
COVID-19: A randomized clinical trial. BMJ 2020 April 15. [Epub
ahead of print]
- Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. Avifavir for
treatment of patients with moderate COVID-19: Interim results of a
phase II/III multicenter randomized clinical trial. Clin Infect Dis
2020 August 9. [Epub ahead of print]
- Weiss A, Jellingsø M, Sommera MOA. Spatial and temporal dynamics of
SARS-CoV-2 in COVID-19 patients: A systematic review and
meta-analysis. EBioMedicine 2020; 58:102916.
- RECOVERY Collaborative Group. Dexamethasone in hospitalized patients
with COVID-19 - preliminary report. N Engl J Med 2020 July 17;
58:102916.
Table 1 . Univariate and multivariate analysis among symptomatic
COVID-19 patients and risk factors associated with composite poor
outcome (defined as at least one of the outcomes: requiring high-flow
oxygen therapy, being intubated with mechanical ventilation, admission
to ICU, or death).